BridgeMD
New treatment option for Parkinson Disease
Official title Personalized Stimulation Loop for Neurorehabilitation in Parkinson: a Proof-of-principle Study
ClinicalTrials.gov ID: NCT07082595
What this study is testing
- What it's testing
- Parkinson's disease (PD) is a neurodegenerative disease that affects about 1% of the elderly population and accounts for substantial disability and health care costs. Disability is largely driven by mobility deficits caused by impaired gait.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Idiopathic Parkinson's disease with gait and postural stability deficits
- ≥18 years of age
- UPDRS III gait scores 1-3
- UPDRS III postural instability scores 1-3
- Prescribed rehabilitation therapy
You likely can't join if
- Cognitive impairment, Montreal Cognitive Assessment (MoCa) \< 20
- Other neurological or medical condition that caused sustained clinically relevant gait and/or postural stability deficits
- History of a physical or neurological condition that interferes with study procedures
- Social and/or personal circumstances that interfere with the ability to return for assessments
- Patients taking benzodiazepines or Z-drugs that have a significant effect on sleep EEG
- Recent DBS implant (≤ 6 months)
See the full eligibility criteria
- Idiopathic Parkinson's disease with gait and postural stability deficits
- ≥18 years of age
- UPDRS III gait scores 1-3
- UPDRS III postural instability scores 1-3
- Prescribed rehabilitation therapy
- Informed consent as documented by signature
- Adjustments in dopaminergic medication and DBS stimulation to improve
- Cognitive impairment, Montreal Cognitive Assessment (MoCa) \< 20
- Other neurological or medical condition that caused sustained clinically relevant gait and/or postural stability deficits
- History of a physical or neurological condition that interferes with study procedures
- Social and/or personal circumstances that interfere with the ability to return for assessments
- Patients taking benzodiazepines or Z-drugs that have a significant effect on sleep EEG
- Recent DBS implant (≤ 6 months)
- Inability to perform outcome assessments without walking aid
- Skin disorders/problems/allergies in face/ear area that could worsen with electrode application (e.g. nickel allergy)
The study team makes the final eligibility decision.
Where it's taking place
- Zurich, Canton of Zurich, Switzerland
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Zurich, Canton of Zurich, Switzerland. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.